Nabriva Therapeutics

Nabriva Therapeutics Employees

5 people indexed:

Christopher Naftzger

Interim CEO, General Counsel and Corporate Secretary

4kw0duk2yuq.qulxd38j@74jl608.x29 Sign up to see email

lwyuj86wyly.10uyy5y8@7d5dxq1.6k5 Sign up to see email
Dan Dolan

Chief Financial Officer

twf.9zu2y@e89qp4x.2ht Sign up to see email

3zy.1100u@4tt10z6.p8j Sign up to see email
Lisa Dalton

Board Member

ffyf.k03f4p@70f42u3.z0w Sign up to see email

hy37.gze5z1@725z1qq.p6k Sign up to see email
Mark Corrigan

Board Member

6se5.x906uh66@1z38f6y.wz1 Sign up to see email

z7el.9slypwxf@5dyylet.ffx Sign up to see email
Steven Gelone

Board Member

099y81.qp4y0p@6p3uzq8.39x Sign up to see email

w8kq9q.hk511y@j4wx12u.fhh Sign up to see email

Nabriva Therapeutics Company Information

Nabriva Therapeutics operates as a commercial-stage biopharmaceutical entity primarily engaged in the development and commercialization of novel anti-infective agents to combat serious infections. The company’s flagship product, XENLETA® (lefamulin), has been approved by the FDA for oral and IV use in treating community-acquired pneumonia (CAP) and by the European Medicines Agency on July 28, 2020. Additionally, Nabriva offers a Named Patient Program that allows healthcare professionals in select countries where XENLETA® is not available to access the drug. The company is also developing CONTEPO™ (fosfomycin for injection), aimed to be a first-in-class epoxide antibiotic in the U.S. for treating complicated urinary tract infections, including acute pyelonephritis. Despite submitting a New Drug Application for CONTEPO™, the FDA issued a Complete Response Letter due to travel restrictions preventing onsite inspections. Nabriva Therapeutics maintains operations in the United States, Austria, and Ireland and actively seeks collaboration and licensing opportunities to expand its portfolio and address infectious diseases globally.

Report inaccurate information